TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments

TREX1 Inhibitor Assays
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
Read more
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases

cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
Read more
No Comments

BellBrook Labs Receives NIH Funding for Novel Approach to Stimulating Antitumor Immunity

TREX1 Press Release Graphic
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small
Read more
No Comments

Join Us for SLAS 2021 Virtual Conference

SLAS 2021
BellBrook Labs will be exhibiting at SLAS 2021, January 25-27. Due to the pandemic, this year’s meeting will, of course, be virtual. Although, we are sad that we won’t be able to meet with you in person this year there are still plenty of opportunities to interact. We will have a virtual booth that is
Read more
No Comments

SLAS 2020 – Discover HTS Assays for Drug Discovery

SLAS 2020 Conference
  BellBrook Labs will exhibit and present posters at the upcoming SLAS 2020 conference in San Diego, CA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting ENPP1, studying CD73, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
Read more
No Comments

BellBrook Labs Recap of SLAS 2019 in Washington DC.

SLAS 2019
BellBrook Labs will be exhibiting and have poster presentations at the upcoming SLAS conference. During the meeting, BellBrook will have information available demonstrating a variety of applications for Transcreener HTS tools. Stop by booth #1702 where you can receive your copy of “A Guide to Measuring Drug-Target Residence Times with Biochemical Assays.” We are looking forward
Read more
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Read more
No Comments

Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation

When the body responds to a bacterial pathogen, fragments of bacterial peptidoglycan alert a human host to the presence of a microbial invader. A receptor named NOD2 recognizes the peptidoglycans and sounds the alarm, initiating immune responses by causing the production of pro-inflammatory cytokines via NF-κB and MAP kinase pathways 1. In this manner, NOD2
Read more
No Comments

Discovery on Target 2017

  Here is what you may have missed… Exhibition Learn about our new AptaFluor SAH Methyltransferase Assay Discuss which HTS assays might be a fit for your research Discover how BellBrook Labs’ services can help accelerate your drug discovery program Presentations/Talks Targeting the cGAS-STING Pathway Using a Homogenous, HTS Compatible Transcreener® cGAS Assay Thursday, September
Read more
No Comments

New Publication: HTS Method for Measuring Drug Residence Time

View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
Read more
No Comments